Join to view full profile
9555 SW Barnes RdSte 150Portland, OR 97225
Phone+1 503-297-7403
Fax+1 503-384-9908
Dr. Andersen is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of Kansas School of MedicineFellowship, Hematology and Medical Oncology, 1999 - 2002- University of Kansas School of MedicineResidency, Internal Medicine, 1996 - 1999
- University of Kansas School of MedicineClass of 1996
Certifications & Licensure
OR State Medical License 2004 - 2027
WA State Medical License 2004 - 2026
American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification iKnowMed EHR, McKesson, 2012, 2014-2017
- CMS Meaningful Use Stage 2 Certification iKnowMed Generation 2, McKesson, 2012, 2014-2017
- CMS Meaningful Use Stage 1 Certification iKnowMed™ EHR, US Oncology, 2012, 2014-2017
Clinical Trials
- Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy Start of enrollment: 2008 Dec 10
- A Phase III Randomized Trial of Metformin vs Placebo in Early Stage Breast Cancer Start of enrollment: 2010 Aug 13
- Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer Start of enrollment: 2011 Feb 08
Publications & Presentations
PubMed
- 1 citationsAtezolizumab in early triple-negative breast cancer: the randomized phase 3 NSABP B-59/GeparDouze trial.Sibylle Loibl, Gong Tang, Valentina Nekljudova, Priya Rastogi, Sivaramakrishna Rachakonda
Nature Medicine. 2026-09-01 - 25 citationsTROPION-Breast04: a randomized phase III study of neoadjuvant datopotamab deruxtecan (Dato-DXd) plus durvalumab followed by adjuvant durvalumab versus standard of care...Heather L McArthur, Sara M Tolaney, Rebecca Dent, Peter Schmid, Jamil Asselah
Therapeutic Advances in Medical Oncology. 2025-01-01 - 13 citationsNeoadjuvant talazoparib in patients with germline BRCA1/2 mutation-positive, early-stage triple-negative breast cancer: exploration of tumor BRCA mutational status.Melinda L Telli, Jennifer K Litton, J Thaddeus Beck, Jason M Jones, Jay Andersen
Breast Cancer. 2024-09-01
Press Mentions
Preparing for a Baby After Cancer - US NewsJune 19th, 2015
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: